Table 1: Assessment of DCs/tumor fusions based vaccine.

Patients DCs/tumor fusionsCoadministrationClinical responsesRef.
Dendritic cellsTumor cells

Melanoma ( 𝑛 = 1 6 )AllogeneicAutologous1 (CR)[98]
1 (PR)
5 (SD)
9 (PD)

Glioma ( 𝑛 = 8 )AutologousAutologous2 (PR)[101]
1 (SD)
5 (PD)

Melanoma ( 𝑛 = 1 7 )AutologousAutologous1 (PR)[99]
1 (SD)
15 (PD)

Melanoma ( 𝑛 = 1 1 )AllogeneicAutologousrh IL-21 (SD)[100]
10 (PD)

Glioma ( 𝑛 = 1 2 )AutologousAutologousrh IL-123 (PR)[100]
2 (MR)
4 (SD)
3 (PD)

Breast cancer ( 𝑛 = 2 )AutologousAutologousrh IL-121 (SD)[100]
1 (PD)

Gastric/Colorectal cancer ( 𝑛 = 3 )AutologousAutologousrh IL-121 (SD)[100]
2 (PD)

Ovarian cancer ( 𝑛 = 3 )AutologousAutologousrh IL-122 (SD)[100]
1 (PD)

Melanoma ( 𝑛 = 4 )AutologousAutologousrh IL-124 (PD)[100]

Breast cancer ( 𝑛 = 1 0 )AutologousAutologous2 (PR)[21]
1 (SD)
7 (PD)

Renal cell carcinoma ( 𝑛 = 2 0 )AllogeneicAutologous2 (PR)[22]
8 (SD)
10 (PD)

Hepatocellular carcinoma ( 𝑛 = 1 )AutologousAutologous1 (PD)[88]

CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progressive disease.